Merck and Pythia Biotech Signed a MOU on Using Organ-on-Chip Technology to Develop Next-Generation Platform for Drug Testing
 
On June 9, Merck KGaA, Darmstadt, Germany and Taiwan startup Pythia Biotech signed a Memorandum of Understanding (MOU) to strengthen their cooperation in utilizing organ-on-chip technology, which mimics the microenvironment of the human body, as a next-generation platform for drug testing.
 
Merck will provide resources such as assistance and international venture capital referrals.
 
Additionally, Pythia Biotech is actively exploring the application of organ-on-chip technology for selecting the optimal drug treatment plans for cancer patients.
 
To learn more about their cooperation, please visit #GlobalBio's: https://lnkd.in/g3tXbsn2
 
 
#MerckTaiwan #Healthcare #MOU #BioConvergence #BioMedical #OrganOnChip #Pythia #ScienceAndTechnology